Kristin Anderson, PhD – Fred Hutchinson Cancer Center
Allison Betof Warner, MD, PhD – Memorial Sloan Kettering Cancer Center
Ashley Koegel, MD – Bristol Myers Squibb
- Aleksei Tikhonov, PhD – Gustave Roussy
The audience for the ECS Speed Mentoring Event includes Students and Scientists-in-Training who are seeking one-on-one career mentorship from experts in the field of cancer immunotherapy. Clinical fellows and clinical residents are also welcome to apply for this event. All mentees should be prior to assistant professorship. SITC membership is required for participation in the ECS Speed Mentoring event. Click here to become a member.
The inaugural ECS Speed Mentoring Event will provide early career scientists the opportunity to receive mentorship from an expert in the field of cancer immunotherapy in a one-on-one setting. Hosted by SITC's Early Career Scientist Committee, mentees will be matched with an expert mentor in one of the following three categories: industry/non-academic careers, basic/translational science, or clinical science. Each mentee will receive one 15 minute discussion with an expert mentor. The remaining time will provide an opportunity for networking in an adjoining area. Mentees are required to apply to participate in this mentoring event and, upon acceptance, will be required to submit their CV and headshot.
*Mentors are subject to change and one-on-one time with any particular mentor or mentoring in any particular topic cannot be guaranteed.
Genevieve Boland, MD, PhD – Massachusetts General Hospital
Genevieve M. Boland, MD, PhD, FACS is an Associate Professor at Harvard Medical School and Section Head of Melanoma/Sarcoma Surgery at the Massachusetts General Hospital. Her primary clinical focus is on melanoma and cutaneous oncology. She undertook combined MD/PhD training, completing a PhD in Cell and Tissue Engineering at the National Institutes of Health focusing on signaling pathways in adult, human mesenchymal stem cells.
She graduated cum laude from Thomas Jefferson University as a member of the Alpha Omega Alpha medical honor society and completed her general surgical training at Massachusetts General Hospital. Following this, she completed a clinical fellowship in Complex General Surgical Oncology and a combined research fellowship at the University of Texas MD Anderson Cancer Center. She joined the MGH Division of Surgical Oncology and is focused on the clinical management of skin cancer patients. She is board certified in General Surgery and Complex General Surgical Oncology, and she is a Fellow of the American College of Surgeons.
Dr. Boland has received many awards including the American Surgical Association Foundation Fellowship, the Association of Women Surgeons Research Fellowship, the Harvard Catalyst Medical Research Investigator Training Award, the Karin Grunebaum Cancer Foundation Fellowship, and the Society of Surgical Oncology Clinical Investigator Award. She is Director of the Surgical Oncology Research Laboratories and an Associate Member of the Broad Institute of MIT and Harvard. Her laboratory is currently focused on molecular profiling of melanoma, characterization of molecular and immunological changes that occur during immunotherapy, and the identification of circulating biomarkers of cancer.
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
Dr. Cesano is ESSA’s Chief Medical Officer. Prior to joining ESSA, Dr. Cesano served as Chief Medical Officer at NanoString Inc., focusing on the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response and resistance. Previously, Dr. Cesano was the Chief Medical Officer at Cleave Biosciences, Inc., and Nodality, Inc. Throughout her career, Dr. Cesano has held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped advance various oncology drugs through late-stage development and FDA approvals.
Early in her professional career, Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania, and she has authored over 100 publications. Dr. Cesano received an M.D. summa cum laude, a Board Certification in Oncology and a Ph.D. in Tumor Immunology from the University of Turin.
Daniel S. Chen, MD, PhD – Engenuity Life Sciences
Nir Hacohen, PhD – Broad Institute
Dr. McQuade is an Assistant Professor and Physician Scientist in Melanoma Medical Oncology at the UT MD Anderson Cancer Center. Dr. McQuade completed her medical training at Baylor College of Medicine, residency at the University of Pennsylvania, and her fellowship at MD Anderson Cancer Center prior to joining the faculty in 2018. Her research focuses on how host factors and the microbiome influence tumor biology and the anti-tumor immune response with the goal of developing novel strategies to improve outcomes with approved therapies in melanoma and other cancers. This includes work showing that obesity is paradoxically associated with improved outcomes with both immune and targeted therapy in melanoma published in Lancet Oncology in 2018 and work showing connections between diet, the microbiome and response to immunotherapy published in Science in 2021. Her translational lab is focused on elucidating the biological basis of the “obesity paradox” and mechanisms underlying diet-microbiome-immunity interactions. She leads both large cohort studies with robust biospecimen collection as well as dietary intervention clinical trials with parallel preclinical studies.
Ira Mellman, PhD – Genentech
Avery D. Posey, Jr., PhD – University of Pennsylvania, Perelman School of Medicine